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The incidence of oesophageal adenocarcinoma has increased by 500% over the past 30 years [1].
Improved understanding of the mechanisms of neoplastic progression provides an opportunity to
reverse this trend. A thorough review of emerging strategies aiming to prevent the formation of oeso-
phageal malignancy is presented. These include dietary modiﬁcation, chemoprevention, early endoscopic
identiﬁcation and treatment of premalignant disease, and the potential for a non-endoscopic screening
test. Oesophageal adenocarcinoma has become a major public health problem in the West and it is
essential that clinicians are fully informed of risk reduction strategies so that they can be actively pro-
moted in the community.
Crown Copyright © 2014 Published by Elsevier Ltd on behalf of Surgical Associates Ltd. All rights
reserved.1. Introduction
The incidence of oesophageal adenocarcinoma is rising more
rapidly than any other solid tumour in the Western world with an
increase of 500% recorded over the past 30 years [1]. Despite cen-
tralisation of cancer services leading to improvements in operative
mortality, overall 5 year survival remains just 10% reﬂecting the late
presentation of oesophageal tumours [2].
There is a critical need to develop strategies to limit the occur-
rence of invasive adenocarcinoma either by modulation of cellular
neoplastic pathways or by improvements in early detection and
aggressive treatment of Barrett’s-associated oesophageal dysplasia.
The development of oesophageal adenocarcinoma follows awell
described sequential progression from normal squamous mucosa,
tometaplasia (Barrett's oesophagus), and then low-grade and high-
grade dysplasia. The recognition of glandular dysplasia as the
premalignant lesion has facilitated the development of strategies tot, Leadon House, Gloucester-
GL1 3NN, UK.
nd).
vier Ltd on behalf of Surgical Assoenable early detection and intervention, with the aim of preventing
progression to malignancy. This approach has been successful in
the setting of premalignant cervical intraepithelial neoplasia and
adenomatous colonic polyps, and it is hoped could similarly
signiﬁcantly decrease the mortality and morbidity associated with
oesophageal cancer.
This article reviews the current evidence supporting strategies
to prevent the formation of oesophageal adenocarcinoma,
including dietary and lifestyle factors, chemomodulation, and
emerging techniques for identifying and eradicating premalignant
dysplasia. The role of Barrett's surveillance is discussed, as is the
potential for non-endoscopic population-based screening using
promising molecular techniques.
2. Lifestyle and dietary factors
Avoidance of established oesophageal cancer risk factors and
awareness of protective factors are widely endorsed and can have
far-reaching health and economic beneﬁts [3e6]. Well documented
risk factors include obesity, smoking, excessive alcohol intake, and
chronic gastrointestinal reﬂux disease (GORD). Centripetal obesity
and chronic GORD are particularly associated with adenocarcinomaciates Ltd. All rights reserved.
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recent years. Eliminating obesity could signiﬁcantly decrease
oesophageal adenocarcinoma incidence (up to three fold), and
educating patients of the clinical presentation of GORD and
encouraging them to seek early medical attention and treatment
may have an even greater beneﬁt [3,6].
Dietary agents including vitamins C and E, selenium and ca-
rotenoids have been shown to possess antioxidant properties
which can reduce DNA damage and up-regulate apoptosis thereby
potentially minimising the risk of cancer [7,8]. Encouraging results
have been obtained from animal studies where vitamin E supple-
mentation has been shown to suppress the development of oeso-
phageal adenocarcinoma [9]. However, these promising results are
not universally reported [10] and further work is needed to corre-
late speciﬁc dietary supplements with cancer risk as well as to
address doseeresponse and duration requirements.
3. Chemoprevention
Several well-established medications have demonstrated evi-
dence of a chemoprotective effect and are currently undergoing
substantial investigation. These include aspirin, non-steroidal anti-
inﬂammatories, and proton pump inhibitors. In addition to these
established drugs, there is considerable optimism that our
improving understanding of carcinogenesis will allow develop-
ment of highly targeted disease speciﬁc agents.
The only widely recommended medication for chemopreven-
tion and/or symptom control in patients with Barrett's oesophagus
is protein pump inhibitors (PPIs). Recurrent pulsatile acid reﬂux in
the lower oesophagus has been shown to predispose to the
development of Barrett's oesophagus, a potential precursor of
oesophageal adenocarcinoma. By reducing the acidic component of
oesophageal reﬂuxate PPIs decrease cellular differentiation and
down-regulate COX-2 expression. However, to date clinical trials of
PPIs in Barrett's oesophagus have failed to demonstrate a signiﬁ-
cant reduction in adenocarcinoma rates even in animal models
[11,12], although initial fears that PPIs could actually stimulate
hyperproliferation of Barrett's epithelium by induction of hyper-
gastrinaemia appear dumfounded [13e15].
Both aspirin and non-steroidal anti-inﬂammatory drugs
(NSAIDs) have been associated with a reduction in progression to
oesophageal adenocarcinoma when taken regularly and for a suf-
ﬁcient duration [16,17]. The precisemechanisms for this are unclear
but it is most likely mediated via inhibition of COX-2 with simul-
taneous inhibition of other inﬂammatory pathways. High dose
aspirin has been shown to produce a 33% reduction in the odds of
developing oesophageal adenocarcinoma, with evidence of a dos-
eeresponse effect in reducing the odds of progression with
increasing dosage [18]. Its primary current clinical indication is to
decrease mortality from ischaemic heart disease, peripheral
vascular disease and cerebrovascular disease albeit the lower dose
of 75 mg per day is effective for these purposes. Prolonged aspirin
usage, particularly at higher doses, confers a risk of serious
gastrointestinal haemorrhage and could therefore not been rec-
ommended as a sole primary prevention agent [18].
The Aspirin Esomeprazole Chemoprevention Trial (AspECT) trial
is a large ongoing phase 3 UK-based randomised trial which aims to
assess the role of aspirin plus esomeprazole on the overall mortality
of patients with Barrett's oesophagus [19]. It is hypothesised that
the combined use of aspirin with esomeprazole could mitigate the
risks of gastrointestinal haemorrhage whilst providing combined
vascular and anti-cancer beneﬁts. It is important to highlight that
chemoprevention using aspirin does not appear effective in all
patients with Barrett's oesophagus as up to 80% have been shown to
derive no cancer prevention beneﬁt [20]. In addition, if the AspECTtrial is to recommend esomeprazole-aspirin therapy for patients
with Barrett's oesophagus it will likely spawn further studies
aiming to establish ways of determining the 20% of patients with
Barrett's oesophagus who appear to derive beneﬁt from aspirin
therapy [20].
Statins and 5-aminosalicyclic acid (5-ASA) compounds are also
widely reported to possess chemopreventive properties although
the later have a considerable sideeeffect proﬁle making their use
solely for chemoprevention impractical [21]. A recent meta-
analysis of 11 observational studies examining adenocarcinoma
development in Barrett's oesophagus included 317 cancers and
1999 controls and demonstrated that routine statin use was asso-
ciated with a signiﬁcant reduction in the incidence of adenocarci-
noma (OR¼ 0.57; 95% CI: 0.43e0.75). Pooled data from population-
based studies also showed that statin use was associated with a
lower incidence of all combined esophageal cancers (OR ¼ 0.81;
95% CI: 0.75e0.88) in an unselected population cohort [22]. Large-
scale trials with long-term follow-up are currently underway to
further evaluate and quantify the potential beneﬁts of statin use in
the prevention of oesophageal and other gastrointestinal
malignancies.
It is hoped that the development of molecular techniques will
enable future biotherapeutic targeting of the molecular modulators
essential for carcinogensis. Since many common cancers share
similar origins with dysfunction in mismatch-repair mechanisms,
oncogenes and angiogenic pathways it is feasible that novel agents
could demonstrate widespread oncological chemopreventive
beneﬁts.
4. Intervention for oesophageal dysplasia
Barrett's oesophagus confers a 30e125 times increased risk of
oesophageal adenocarcinoma and has a population prevalence of
around 2% [23]. The reported risk of progression from Barrett's
oesophagus to adenocarcinoma varies but is in the region of 0.3%
per year [24]. However, the development of dysplastic Barrett's
oesophagus confers a much higher risk of progression to adeno-
carcinoma. There is clear evidence for the early endoscopic treat-
ment of high-grade dysplasia (HGD) which can prevent malignant
progression and confer long-term survival beneﬁts [25e29]. There
is also very recent evidence from amulti-centre randomised trial to
support the early endoscopic treatment of Barrett’s-associated low-
grade dysplasia (LGD) provided the diagnosis has been conﬁrmed
by two expert gastrointestinal histopathologists [30]. After 3 years
of follow-up, RFA therapy was shown to decrease the risk of pro-
gression from LGD to adenocarcinoma by 7.4% compared to endo-
scopic surveillance alone (1.5% ablation group vs 8.8% control
group; 95% CI 0%e14.7%; p ¼ 0.03) [30].
Endoscopic mucosal resection (EMR) is recommended for exci-
sion and accurate staging of focal dysplastic lesions and has been
shown to provide complete remission in 97% of patients with high-
grade lesions smaller than 2 cm in diameter [31]. A consensus of
international experts support the subsequent use of radiofrequency
ablation (RFA) to the whole Barrett's segment once focal lesions
have been excised [29]. This policy destroys the underlying ﬁeld
change associated with dysplastic Barrett's oesophagus and
thereby minimises the risk of recurrence.
RFA has recently become the most favoured ablation technique
and has demonstrated eradication of Barrett's oesophagus with or
without dysplasia in up to 98% of patients at 21 months, with a very
low incidence of complications [18,32,33]. This effect has also been
shown to be durable at 3 years although longer term follow-up data
is awaited.
Other ablation therapies including photodynamic therapy,
argon plasma coagulation (APC), and multipolar electrocoagulation
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omised controlled trials [29,34e36]. However, these have generally
demonstrated higher complications rates, or are less amenable to
treating large circumferential Barrett's than RFA [37,38].
There is a clear evidence base to support the treatment of Bar-
rett’s-associated HGD, along with emerging evidence to support
early treatment of LGD [29e36]. However, the use of endoscopic
intervention, particularly techniques that target focal lesions such
as EMR and APC, is complicated by difﬁculties recognising
dysplastic lesions in the oesophagus. Up to 57% of dysplastic lesions
may be missed by random Barrett's biopsy protocols and even
experienced endoscopists using high-deﬁnition white light
endoscopy will miss some small lesions [39]. A variety of diagnostic
tools have therefore been developed which aim to improve the
sensitivity of index endoscopy for detecting dysplasia (Table 1).
These techniques include confocal microscopy, chromoendoscopy,
narrow band imaging (NBI), optical coherence tomography and
autoﬂuorescence imaging. Although some of these techniques have
demonstrated considerable promise as diagnostic tools, further
work is required to conﬁrm consistently high diagnostic accuracy,
low inter-user variation, acceptable speed of use, and an acceptable
costebeneﬁt proﬁle.
The strong evidence base supporting the efﬁcacy of endoscopic
therapy in HGD has prompted a signiﬁcant shift away from oeso-
phagectomy in the management of HGD. A recent Cochrane review
identiﬁed no RCTs comparing surgery to endoscopic therapy in this
setting [49]. However, a majority of international experts on Bar-
rett's dysplasia consider endoscopic therapy to now be the ﬁrst-line
treatment option in most patients with HGD [29]. All patients must
be fully staged (including EMR and EUS) to exclude ‘iceberg’ tu-
mours [29]. In young patients with long Barrett's segments and
multifocal nodular HGD clinicians must have a particular suspicion
for underlying invasive disease and in this setting oesophagectomy
should be considered early and discussed in a multidisciplinary
meeting and with the patient.5. Screening and surveillance for dysplasia
The evidence that endoscopic therapy performed in specialist
units can potentially eradicate all dysplastic disease in Barrett's
segments supports the current policy of surveillance of patients
with Barrett's oesophagus. However, since rates of progression
from Barrett's to adenocarcinoma are low there are concerns that
the costs, risk of complications, and impact on quality of life asso-
ciated with repeated biennial endoscopy does not justify theTable 1
Advanced endoscopic imaging modalities aiming to improve detection and targeted trea
Diagnostic modality Reference Technological
High deﬁnition magniﬁcation
endoscopy
May et al., 2004 [40] Increased mag
visualisation
Narrow-band imaging Curvers et al., 2008 [41] Illumination w
visualisation o
Chromoendoscopy Canto et al., 2006 [42] Endoscopic ap
topography
Confocal microscopy Dunbar 2010 [43] 1000 fold mag
visualisation o
Elastic scattering spectroscopy Qiu et al., 2010 [44] Real-time elas
information ab
Raman spectroscopy Huang et al., 2014 [45] Inelastic Rama
between muco
Autoﬂuorescence imaging Kara et al., 2005 [46] Absorption of
ﬂuorescent lig
Molecular detection Bird-Lieberman et al., 2012 [47] Fluorescently-
cellular target
Trimodality imaging Curvers et al., 2011 [48] Combination o
speciﬁcity of ecurrent recommendations for surveillance. The Barrett's Oesoph-
agus Surveillance Study (BOSS) is a large on-going multicentre, UK
based randomised control trial aiming to deﬁne the objective value
of endoscopic surveillance and the most appropriate surveillance
protocol. The BOSS trial randomised patients to either ‘endoscopy
at need’ without routine surveillance, or repeated biennial endos-
copy with a comprehensive biopsy regimen. This trial has ﬁnished
recruiting and interim results are awaited.
Currently there is no screening test for Barrett's oesophagus,
dysplasia or early adenocarcinoma in widespread clinical use.
Endoscopic screening of the general population is not recom-
mended due to the low relative risk of developing dysplasia and
adenocarcinoma, and the invasive nature of the test which is
inappropriate for use as a generic ﬁrst-line screening tool.
There have been attempts to develop scoring systems using
patient demographics and symptoms to predict high risk groups to
which endoscopic screening could be offered [50e52]. Currently
patients with multiple risk factors including chronic GORD, obesity,
age over 50 years and male sex are appropriate for referral for
endoscopy however the yield of treatable oesophageal pathology is
small and the sensitivity and speciﬁcity of these scoring systems are
low.
Work is on-going to develop future non-invasive screening tests.
It is hoped that these could employ molecular techniques to
identify patients with susceptible phenotypes who could beneﬁt
from early endoscopic therapy. An example is the development of a
non-endoscopic immunocytological device (Cytosponge) which is
currently being trialled in three centres in the UK. The Barrett's
Oesophagus Screening Trial (BEST2) requires patients to swallow a
small capsule which dissolves into a 3 cm Cytosponge in the
stomach. The sponge is then withdrawn back up the oesophagus
and collects a sample of adhering epithelial cells which are then
assessed for a range of predictive biomarkers.
The Chemoprevention of Premalignant Intestinal Neoplasia
(ChOPIN) trial is also underway which aims to detect a panel of
serum biomarkers capable of predicting high risk patients. It is
hoped that non-invasive screening tests such as these could facil-
itate safe, accurate and cost-effective population based screening
for treatable early oesophageal neoplasia in the future.6. Prophylactic anti-reﬂux surgery
Studies have demonstrated regression in Barrett's length in
14%e35% of patients following anti-reﬂux surgery. Complete
regression of LGD in 44%e93% of patients has also been reportedtment of oesophageal dysplasia.
basis Phase of development
niﬁcation and resolution enables improved mucosal Phase 3 clinical trials
ith narrow bandwidth green and blue light improves
f mucosal morphology
Licensed for clinical use
plication of dyes to improve mucosal surface Licensed for clinical use
niﬁcation of the mucosal surface allowing
f cellular structures in real-time
Phase 3 clinical trials
tic scattering of white light generates morphological
out cellular structures
Phase 2 clinical trials
n scattering detects subtle biochemical differences
sal cell types
Phase 2 clinical trials
short wavelength light with subsequent release of
ht aids delineation of mucosal lesions
Phase 3 clinical trials
tagged molecular probes selectively bind to speciﬁc
s
Ex vivo trial
f HRME, NBI and AFI improves sensitivity and
ach individual technique
Phase 3 clinical trials
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controlled trials [53e55]. Studies have also failed to show an ab-
solute reduction in rates of oesophageal adenocarcinoma following
anti-reﬂux surgery compared to PPI therapy alone. In addition, any
beneﬁts of anti-reﬂux surgery would need to be considered against
the potential morbidity and economic implications of a widespread
recommendation for prophylactic surgery. For these reasons pro-
phylactic anti-reﬂux surgery is not recommended for patients with
Barrett's oesophagus.
7. Conclusions
The incidence of oesophageal adenocarcinoma is increasing
rapidly and 5 year survival rates remain unacceptably low.
Increasingly the importance of cancer prevention is being recog-
nised by healthcare providers and politicians and development of
promising preventative strategies is now widely supported. The
beneﬁts of dietary and lifestylemodiﬁcation arewell publicised and
have far reaching health and economic value. In addition, mini-
mally invasive endoscopic therapies now have a strong evidence
base and are routinely practiced to treat premalignant oesophageal
dysplasia preventing progression to invasive cancer. However,
identiﬁcation of patients who are at risk remains problematical.
This is partly due to reliance on endoscopic methods of lesion
detection with ‘random’ quadrantic biopsies every 2 cm still rec-
ommended in patients with Barrett's oesophagus as the best
strategy of identifying dysplastic change. Importantly, there also
remains no readily available technique to predict which small
cohort of patients with Barrett's oesophagus will progress to
adenocarcinoma.
Future molecular strategies may enable detection of biomarkers
that predict an individual's risk of oesophageal carcinogenesis us-
ing a non- or minimally-invasive screening test. In addition, it is
hoped that improved understanding of the triggers for disease
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